跳转至内容
Merck
CN

CRISPRICON

Human CRISPRi Control and Effector Kit

登录 查看组织和合同定价。

选择规格

变更视图

关于此项目

NACRES:
NE.02
UNSPSC Code:
12352200
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


packaging

pkg of 12 vials (4x50μL aliquots for each of the 3 kit components)

application(s)

CRISPR

shipped in

dry ice

storage temp.

−70°C

General description

The control kit includes validated positive control targeting RAB1A and non-targeting control for assay set-up and a UCOE KRAB-dCas9 for consistent effector expression across a wide variety of cell lines. The kit is ideal for setting up the screen assay and optimization before using the CRISPRi library pools.

Application

  • Set up and optimization of screen assay
  • Functional Genomics/Target Validation
  • Creation of cell lines stably expressing KRAB-dCas9
  • Validated Positive and negative controls

Biochem/physiol Actions

The power of CRISPR for genome engineering, coupled with the ability to perform large-scale, whole genome, loss-of-function (LOF) screening, has allowed for new breakthroughs identifying gene pathways in drug resistance and disease. CRISPR is most commonly used to create double-stranded breaks that often result in loss of gene function (CRISPR-KO). However, the full extent of CRISPR′s utility extends beyond just targeted cutting of DNA. Nuclease-independent applications of CRISPR provide equal targeting specificity but instead of cutting, CRISPRi allows for targeted interference of gene function by delivering transcriptional repressor domains to a specific target sequence using modified dCas9 + gRNA complexes. Gene knockdown is complementary to CRISPR-KO and CRISPRa (activation) and has distinct advantages over existing loss-of-function strategies like RNAi. We partnered with University of California San Francisco to provide the best-in-class CRISPRi screening tools available.

Features and Benefits

  • Ease of optimization: Validated positive control targeting RAB1A and non-targeting control for assay set up
  • Best in Class UCSF gRNA selection algorithm and optimized (F+E) gRNA scaffold
  • UCOE KRAB-dCas9 for consistent effector expression across a wide variety of cell lines
  • Libraries provided at high functional titer, based on FACs or CFU analysis
  • Use puromycin and or BFP as selection markers

Other Notes

2 Controls and 1 Effector Construct with a minimum concentration of 5x105 TU/mL(via FACS or CFU assay)

CRISPRIE: KRAB-dCas9 - Blasticidin CRISPRi Construct Lentiviral Transduction Particles
CRISPRI01: CRISPRi RAB1A Puromycin Control Transduction Particles
CRISPRI06: CRISPRi Nontargeting Control Puromycin Transduction Particles

For more information about screening with CRISPRi/a please Click Here.


存储类别

12 - Non Combustible Liquids



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库